| 1.96 -0.15 (-7.11%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.39 | 1-year : | 5.86 |
| Resists | First : | 3.76 | Second : | 5.01 |
| Pivot price | 2.78  |
|||
| Supports | First : | 1.74 | Second : | 1.44 |
| MAs | MA(5) : | 2  |
MA(20) : | 3.07 |
| MA(100) : | 8.04 |
MA(250) : | 7.03 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 10.4 |
D(3) : | 8.8 |
| RSI | RSI(14): 26.1 |
|||
| 52-week | High : | 28.6 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARTL ] has closed above bottom band by 19.4%. Bollinger Bands are 61.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.08 | 2.08 - 2.08 |
| Low: | 1.77 - 1.79 | 1.79 - 1.8 |
| Close: | 1.94 - 1.96 | 1.96 - 1.98 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Fri, 07 Nov 2025
Artelo Biosciences Inc expected to post a loss of 82 cents a share - Earnings Preview - TradingView
Tue, 04 Nov 2025
Artelo Biosciences (ARTL) Publishes Key Research on Cancer and F - GuruFocus
Tue, 04 Nov 2025
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer - Yahoo Finance
Sat, 01 Nov 2025
Artelo Biosciences Strengthens Financial Position with New Agreement - The Globe and Mail
Mon, 27 Oct 2025
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer - GlobeNewswire
Wed, 01 Oct 2025
$2M Biotech Funding: Artelo Biosciences Completes Public Offering for Cancer & Pain Drug Development - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 49 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -18.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -103.9 % |
| Return on Equity (ttm) | -356.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | -0.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|